Pliant Therapeutics Gestion

Gestion contrôle des critères 2/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Bernard Coulie

Directeur général

US$5.2m

Rémunération totale

Pourcentage du salaire du PDG	10.7%
Durée du mandat du directeur général	7.2yrs
Propriété du PDG	0.9%
Durée moyenne d'occupation des postes de direction	7.1yrs
Durée moyenne du mandat des membres du conseil d'administration	5.5yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Bernard Coulie a-t-elle évolué par rapport aux bénéfices de Pliant Therapeutics?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Dec 31 2022	n/a	n/a	-US$123m
Sep 30 2022	n/a	n/a	-US$113m
Jun 30 2022	n/a	n/a	-US$109m
Mar 31 2022	n/a	n/a	-US$103m
Dec 31 2021	US$5m	US$556k	-US$97m
Sep 30 2021	n/a	n/a	-US$92m
Jun 30 2021	n/a	n/a	-US$81m
Mar 31 2021	n/a	n/a	-US$75m
Dec 31 2020	US$2m	US$499k	-US$42m
Sep 30 2020	n/a	n/a	US$18m
Jun 30 2020	n/a	n/a	US$19m
Mar 31 2020	n/a	n/a	US$20m
Dec 31 2019	US$2m	US$428k	-US$7m

Rémunération vs marché: La rémunération totale de Bernard ($USD 5.19M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 1.64M ).

Rémunération et revenus: La rémunération de Bernard a augmenté alors que l'entreprise n'est pas rentable.

PDG

Bernard Coulie (56 yo)

7.2yrs

Titularisation

US$5,190,781

Compensation

Dr. Bernard Coulie, Ph. D, M. D., M. B.A., serves as Independent Director at SQZ Biotechnologies Company since July 2021 and serves as its Independent Chairman since November 2022. He serves as President a...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Bernard Coulie	President	no data	US$5.19m	0.91% € 13.8m
Keith Cummings	Chief Financial Officer	4.3yrs	US$1.88m	0.16% € 2.4m
Mike Ouimette	General Counsel & Corporate Secretary	2.5yrs	US$805.04k	0.020% € 302.3k
Johannes Hull	Chief Business Officer	7.1yrs	US$1.65m	0.30% € 4.6m
Éric Lefebvre	Chief Medical Officer	4.9yrs	US$1.97m	pas de données
Rik Derynck	Scientific Founder & Member of Scientific Advisory Board	8.3yrs	pas de données	pas de données
Dean Sheppard	Scientific Founder & Member of Scientific Advisory Board	8.3yrs	pas de données	pas de données
Bill DeGrado	Scientific Founder & Member of Scientific Advisory Board	8.3yrs	pas de données	pas de données
Hal Chapman	Scientific Founder & Member of Scientific Advisory Board	8.3yrs	pas de données	pas de données
Craig Muir	Interim Chief Technology Officer	no data	pas de données	pas de données
Christopher Keenan	Vice President of Investor Relations & Corporate Communications	no data	pas de données	pas de données
Lily Cheung	Chief Human Resources Officer	less than a year	pas de données	pas de données

7.1yrs

Durée moyenne de l'emploi

49yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de 9PT est chevronnée et expérimentée (7.1 années d'ancienneté moyenne).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Bernard Coulie	President	7.2yrs	US$5.19m	0.91% € 13.8m
Rik Derynck	Scientific Founder & Member of Scientific Advisory Board	no data	pas de données	pas de données
Dean Sheppard	Scientific Founder & Member of Scientific Advisory Board	no data	pas de données	pas de données
Bill DeGrado	Scientific Founder & Member of Scientific Advisory Board	no data	pas de données	pas de données
Hal Chapman	Scientific Founder & Member of Scientific Advisory Board	no data	pas de données	pas de données
Gayle Crowell	Independent Director	3.3yrs	US$287.91k	0% € 0
Brian Metcalf	Member of Scientific Advisory Board	no data	pas de données	pas de données
Suzanne Bruhn	Independent Director	6.8yrs	US$288.29k	0.059% € 899.3k
John Curnutte	Independent Director	5.7yrs	US$286.41k	0.049% € 750.6k
Hoyoung Huh	Independent Chairman	5.3yrs	US$308.41k	0% € 0
Smital Shah	Independent Director	4.1yrs	US$288.41k	0% € 0
Bill Greenlee	Member of Scientific Advisory Board	no data	pas de données	pas de données

5.5yrs

Durée moyenne de l'emploi

59yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 9PT sont considérés comme expérimentés (ancienneté moyenne 5.5 ans).

Pliant Therapeutics Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Pliant Therapeutics Appoints Gary Palmer as Senior Vice President of Medical Affairs

Pliant Therapeutics, Inc. Appoints Steve Krognes to Its Board of Directors

Pliant Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Pliant Therapeutics, Inc. Appoints S. Mishima Gerhart as Chief Regulatory Officer

Pliant Therapeutics, Inc. Appoints Minnie Kuo as Chief Development Officer

Pliant Therapeutics, Inc. Appoints Lily Cheung as Chief Human Resources Officer

Recent updates

Pliant Therapeutics Appoints Gary Palmer as Senior Vice President of Medical Affairs

Pliant Therapeutics, Inc. Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating

Pliant Therapeutics, Inc.(NasdaqGS:PLRX) dropped from Russell 2500 Growth Index

Pliant Therapeutics, Inc. Appoints Steve Krognes to Its Board of Directors

Pliant Therapeutics, Inc. Announces Positive Topline Data from A Phase 2A Collagen Pet Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis

Pliant Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Pliant Therapeutics, Inc. Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis

Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Pliant Therapeutics, Inc. Appoints S. Mishima Gerhart as Chief Regulatory Officer

Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Pliant Therapeutics, Inc. Appoints Minnie Kuo as Chief Development Officer

Pliant Therapeutics, Inc. Presents Data from Its Bexotegrast Program At the European Association for the Study of the Liver International Liver Congress

Pliant Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors

Pliant Therapeutics, Inc. Appoints Lily Cheung as Chief Human Resources Officer

Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial

Insufficient new directors

Pliant Therapeutics, Inc. Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis

Neil Exter to Retire as Member of the Board of Directors of Pliant Therapeutics

Third quarter 2022 earnings released: US$0.65 loss per share (vs US$0.75 loss in 3Q 2021)

Pliant Therapeutics Appoints Katharine Knobi to Board of Directors

Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

Second quarter 2022 earnings released: US$0.82 loss per share (vs US$0.64 loss in 2Q 2021)

Pliant Therapeutics Receives FDA Fast Track Designation for Pln-74809 for the Treatment of Primary Sclerosing Cholangitis

Pliant Therapeutics, Inc. Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis

Pliant Therapeutics, Inc.(NasdaqGS:PLRX) dropped from Russell 2000 Growth Index

Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies

Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration

Pliant Therapeutics, Inc. Presents Five Scientific Posters as Part of the 2022 American Thoracic Society International Conference

First quarter 2022 earnings released: US$0.78 loss per share (vs US$0.64 loss in 1Q 2021)

Pliant Therapeutics, Inc., Annual General Meeting, Jun 16, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Pliant Therapeutics Announces Positive Data from Expanded Phase 1b BAL Trial of PLN-74809 Demonstrated Suppression of TGF-ß Signaling in Healthy Volunteers

Pliant Therapeutics, Inc. Announces Positive DSMB Safety Review and Commencement of Enrollment of Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

Pliant Therapeutics Highlights Recent Developments for Lead Program Pln-74809 and Expected 2022 Milestones

Third quarter 2021 earnings released: US$0.75 loss per share (vs US$0.47 loss in 3Q 2020)

Pliant Therapeutics, Inc. Reports Positive Interim Results from Phase 2a PET Imaging Clinical Trial in Patients with Idiopathic Pulmonary Fibrosis

Second quarter 2021 earnings released: US$0.64 loss per share (vs US$1.39 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.64 loss per share

Pliant Therapeutics, Inc. Announces Successful Completion of PLN-1474 Phase 1 Study and Development Transition to Global Pharmaceutical Partner

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day high: €28.60

Investor sentiment improved over the past week

New 90-day high: €26.40

Pliant Therapeutics, Inc. Announces Appointment of David Pyott to Board of Directors

Investor sentiment improved over the past week

New 90-day high: €24.21

Pliant Therapeutics Appoints Mike Ouimette as General Counsel and Corporate Secretary

New 90-day low: €19.00

Pliant Therapeutics, Inc. announced that it expects to receive $45 million in funding

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen